SPRB Spruce Biosciences Inc - marketcomposite.com

SPRB - Spruce Biosciences Inc8:00:00 PM 4/26/2024

Price

$0.70

-0.00 (-0.14%)

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.

Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Topics

30d

Biotechnology1.50%

leak data

Stock news

SPRB

Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting04-22-2024 20:05:00 PM

SOUTH SAN FRANCISCO, Calif., April 22, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.

SPRB

Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know03-27-2024 16:00:09 PM

Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SPRB

Revenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)03-23-2024 12:47:18 PM

The latest analyst coverage could presage a bad day for Spruce Biosciences, Inc. ( NASDAQ:SPRB ), with the analysts...

SPRB

Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why03-21-2024 14:20:00 PM

Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.

SPRB

Spruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target Price03-16-2024 12:59:40 PM

Spruce Biosciences, Inc. ( NASDAQ:SPRB ) investors will be delighted, with the company turning in some strong numbers...

SPRB

Spruce Biosciences Inc (SPRB) Reports Full Year 2023 Financial Results Amid Clinical Trial Setbacks03-13-2024 21:33:15 PM

Strategic Cost Reductions Extend Cash Runway Through 2025 Despite Clinical Challenges

SPRB

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates03-13-2024 20:08:00 PM

SOUTH SAN FRANCISCO, Calif., March 13, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.

SPRB

Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH03-13-2024 20:01:00 PM

SOUTH SAN FRANCISCO, Calif., March 13, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-203 study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205 study of tildacerfont in pediatric classic CAH.

SPRB

Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference01-30-2024 21:05:00 PM

SOUTH SAN FRANCISCO, Calif., January 30, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 2:40 p.m. ET.

SPRB

Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia01-22-2024 13:00:00 PM

SOUTH SAN FRANCISCO, Calif., January 22, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH).